Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

New Multimode Microplate Reader Delivers High Resolution Performance

By BiotechDaily International staff writers
Posted on 07 Oct 2013
Image: The Mithras2 LB 943 Multimode Monochromator Reader (Photo courtesy of Berthold Technologies).
Image: The Mithras2 LB 943 Multimode Monochromator Reader (Photo courtesy of Berthold Technologies).
A newly available next generation microplate reader performs luminescence, fluorescence, and absorbance measurements with the sensitivity and resolution usually obtained only from separate, dedicated instruments.

The Berthold Technologies (Bad Wildbad, Germany) Mithras2 LB943 microplate reader is a high-end multimode reader based on monochromator technology. The instrument is equipped with two double monochromators with high blocking efficiency and high f-number (increased transmission) for filter free absorbance and fluorescence measurements.

The Mithras2 was designed to carry out an impressive variety of assays including Luminescence, BRET (Bioluminescence Resonance Energy Transfer), fluorescence, FRET (Fluorescence Resonance Energy Transfer), fluorescence polarization (FP), UV/VIS absorbance, time-resolved fluorescence, and time-resolved-FRET. To accomplish these varied tasks the instrument was designed with a proprietary optical system consisting of separate paths for different reading technologies, thus offering quality analysis usually obtained only from separate dedicated instruments.

The instrument can be configured for up to four reagent injectors programmed to dispense multiple activators or detection reagents with user-adjustable volumes at any time during the measurement process. The injectors are based on proprietary JET injection technology that delivers superior accuracy and precision. Variable injections speeds and "bio-friendly" materials enable injection of live cells.

The Mitras2 can be used to measure enzyme activities, phagocytosis, calcium flux, cell viability, apoptosis, immunoassays, protein and nucleic acid concentrations, and protein-protein interactions. Single and multiple endpoint measurements as well as kinetic and scanning measurements can be performed. The data can be displayed numerically and graphically and may be printed or exported to a spreadsheet.

Related Links:

Berthold Technologies




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.